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Profound challenges confront societies worldwide due to the growth of end-stage renal disease (ESRD). Meeting
these challenges requires a sober assessment of how overall global health trends affect ESRD, coupled with an
understanding of how progress in the care of ESRD patients is most appropriately measured and monitored. For
many affluent countries, incident ESRD rates have stabilized since about the middle of the last decade. For example,
the number of new cases in the USA has remained stable at approximately 110,000 per year during this period,
while in Japan, growth in annual incident counts appears to have stabilized as of 2012. However, incidence rates
rose for many developing countries. An immense “renal replacement therapy (RRT) gap,” the difference between
the number of people receiving RRT and the number needing it, was recently described, highlighting the
magnitude of the difficulties these countries face as they continue to develop. To guide efforts to improve care,
broad goals should be established by the worldwide renal health care community. For countries without universal
dialysis access, expansion of RRT accessibility should be the first target in order to reduce the RRT gap; for countries
that have moved beyond this stage, the goals should include reductions in ESRD incidence rates; all-cause,
cardiovascular, and infection-related death rates; and cardiovascular- and infection-related hospitalizations. To
inform judgements about progress in this area, measures beyond the traditional standardized mortality ratio are
needed. Carefully determining trends over time within a given country, such as is done by the World Health
Organization, might prove to be a more useful way to determine progress in combating ESRD and its complications.
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Profound challenges confront societies worldwide as a
result of the growth of kidney disease in general and of
end-stage renal disease (ESRD) in particular. Predictions
about likely future increases in the maintenance dialysis
population suggest that the burden of providing mainten-
ance dialysis in coming decades will be daunting [1–4].
However, the difficulties faced by each country are likely
to be unique, given the national differences in population
structure, socioeconomic profile, and culture. Meeting
these challenges requires a sober assessment of how over-
all global health trends affect ESRD, coupled with an un-
derstanding of how progress in the care of ESRD patients
is most appropriately measured and monitored. Such* Correspondence: acollins@cdrg.org
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around the world to make difficult choices as they seek to
satisfy competing health priorities.Overall global health trends
Trends in ESRD care are intimately linked with broader
developments in public health. Fortunately, recent de-
cades have witnessed some welcome developments in
the general population. Using the framework of the
World Health Organization (WHO), which compiles
worldwide data on health outcomes, causes of death can
be broadly divided into those resulting from communic-
able diseases and from non-communicable diseases
(NCDs) [5]. Because of the stark differences in socioeco-
nomic status between nations, WHO classifies countries
into one of four broad income categories. In developed
countries such as the USA and Japan, national bodies
also track health outcomes and establish population-his article is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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People 2020 initiative [6].
In developed countries, communicable diseases (in the
WHO classification, these include maternal, perinatal,
and nutritional conditions) contribute to only a modest
percentage of deaths, as might be expected: <13 % in
Japan and <7 % in the USA, UK, France, Canada, and
Australia. As a result, most public health efforts in de-
veloped countries are focused on NCDs, and WHO set
as its target a 25 % decrease in NCD deaths by 2025 [5].
Fortunately, major strides have been made in addressing
NCDs in developed countries, especially in the realm of
cardiovascular disease (CVD). For example, between ap-
proximately 2000 and 2012, Japan experienced a 30 %
decline in CVD deaths in women and a 24 % decline in
men; in the USA, corresponding numbers are 27 and
30 %. Overall declines of approximately 35 % occurred
in the UK, France, Canada, and Australia during this
period. Declines in CVD deaths have been so prodigious
that cancer is now the leading age-adjusted cause of
death in many developed countries [5].
However, the situation varies considerably in countries
that are not classified as high-income. For example, in
upper–middle income countries such as Brazil, Thailand,
and Malaysia, overall rates of NCDs and of CVD are fall-
ing—a very welcome development—despite persistently
high rates of communicable diseases (11–18 %) relative
to more developed countries. China is a special case
among this economic group: despite enviably low rates
of communicable diseases (5 %, consistent with rates in














Fig. 1 Incidence rates of end-stage renal disease, by selected country, 2000
2014 USRDS AnnualData Report; remaining data: from the 2013 USRDS Annperhaps due to unprecedented urbanization and rapidly
increasing affluence. Further, among lower–middle and
low-income countries, daunting challenges remain: com-
municable disease rates remain very high (e.g., 25 % for
the Philippines, 29 % for India, 37 % for Cambodia, and
67 % for the Democratic Republic of Congo) at the same
time that NCD death rates are unchanged (India and
Cambodia) or increasing (the Philippines and the Demo-
cratic Republic of the Congo) [5].
Health trends in ESRD
As with NCD- and particularly CVD-related death, some
promising developments have occurred regarding ESRD.
For many affluent countries such as the USA and West-
ern European countries, incident ESRD rates appear to
be relatively stable since about the middle of the last
decade, as shown in Fig. 1. However, during this same
period, incidence rates rose for many developing coun-
tries, such as Bangladesh, Malaysia, Argentina, and
Chile, suggesting that the economic status of a country
is associated with the development or recognition of
ESRD or both.
In a developed country with the largest number of dia-
lysis patients, the USA, incidence rates have been stable
since approximately 2003 [7], when the annual percent-
age increase fell to zero for the first time since 1995 [8].
The number of new US cases has remained stable at
approximately 110,000 per year during this period [7].
As shown in Fig. 2a, the incidence rate in 2012, at 359
per million persons, was 6.6 % lower than that in 2003
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Fig. 2 a Incidence rate of end-stage renal disease, per million population, in the USA; b percent change in incidence rates of end-stage renal
disease, by selected demographic category, in the USA
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People 2020 goal of 344 per million persons [6].
Perhaps even more impressive, certain traditionally
disadvantaged groups experienced higher-than-expected
improvements, such as African Americans (15 % de-
crease), American Indian/Alaskan natives (24 % de-
crease), Hispanics (17 % decrease), and women (12 %
decrease), as shown in Fig. 2b [8]. This is a welcome out-
come with implications well beyond the USA, since
many other developed countries also have substantial
underserved populations at risk for ESRD, such as abori-
ginal peoples in Canada and Australia and economic
and political migrants from Africa, the Middle East, and
Asia in Europe [9–13]. However, it is far from clear why
incident counts have stabilized: improved control of dia-
betes, hypertension, and, perhaps, hyperlipidemia maybe posited, but whether this is truly the reason is
uncertain.
At the same time, life expectancy for patients receiving
maintenance dialysis has risen steadily in many developed
countries. For example, as shown in Fig. 3, the unadjusted
death rate in the USA declined by approximately 20 % be-
tween 2003 and 2012 [7]. This corresponds to an increase
in the mean survival on dialysis of about 1 year, or about
20 %, and an immense number of deaths prevented during
that time. Paradoxically, this creates a situation in which
improvement in the care of prevalent ESRD patients ne-
cessarily means that the absolute number of patients re-
ceiving maintenance dialysis at any time will increase,
suggesting to the uninformed observer that the “ESRD
problem” is worsening. Thus, at present, it is growth in
the prevalent, as opposed to the incident, population that
1,000 lives




























Fig. 3 a Deaths per 100 patient-years, 2004–2011, in US dialysis patients; b number of deaths prevented due to cumulative changes in the death
rate in US dialysis patients since 2003
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population in many developed countries. This is particu-
larly true in the USA, where the number of prevalent dia-
lysis patients is expected to grow from approximately
451,000 in 2012 to approximately 632,000 in 2025 [14].
However, the phenomena described above are not uni-
versal to all developed countries. In Japan, for example,
unique challenges are in evidence. Long the envy of the
rest of the world for the survival of its prevalent dialysis
patients, Japan has, fortunately, experienced a slowing of
growth in the incident counts as of 2012 [15]. Annual
percentage change has hovered around zero for the past
several years, suggesting that Japan may be approaching
a period of stability in annual incident counts that is
manifest in other developed countries. However, unlike
in some other developed countries, 1-, 5-, and 10-year
survival rates have not noticeably improved, and 15- and
20-year survival rates may have declined [16]. While sur-
vival remains much higher in Japan than in other coun-
tries, further improvement should always be sought, and
public policy planners should be aware that stabilization
in the prevalent population is, in reality, a sign that new
efforts to improve dialysis survival must be supported.
Perhaps technological advancements such as the use of
ultrapure dialysis [17–19] might conceivably result in
gains in prevalent patient survival. Additionally, the
Japanese research community should continue to in-
vestigate whether increasing the use of β-adrenergic
blockers, which may benefit some patients [20, 21]
and which are used in comparatively lower amounts
in Japan than in some other countries [22], couldprovide longevity benefits, especially in patients with
heart failure or left ventricular hypertrophy.
Developing countries face a very different set of chal-
lenges. Unlike many affluent countries, where access to
renal replacement therapy (RRT) is universal or near-
universal, developing countries must confront the issue
of access to RRT, which at present is severely limited. A
recent report demonstrates the scope of the problem.
Liyanage et al. [1] systematically reviewed data from
more than 120 countries and, by hypothesizing that
ESRD is related to median age, life expectancy at birth,
and gross national income at the national level, esti-
mated age-specific RRT rates in order to calculate the
world’s “RRT gap” or the difference between the number
of people receiving RRT and the number needing it.
These investigators demonstrated that, as of 2010, the
number of individuals receiving RRT worldwide was
projected as 2.6 million, with about 93 % residing in
high- or high–middle income countries. This effectively
represents a 70-fold prevalence difference between
richer and poor countries when population size is con-
sidered [2]. The number of individuals on dialysis was
projected to more than double by 2030 to 5.4 million,
with the largest growth expected in Asia. Perhaps even
more informative were the projections of the RRT gap:
the authors suggested that only one quarter to one half
of individuals who need RRT receive it, meaning that
the RRT gap might result in 2.3 to 7.1 million premature
deaths.
This finding is conceptually aligned with that of a sec-
ond study, which estimated an approximately 70 %
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2010, fueled by a doubling of the incidence rate [3].
These authors suggested that while changes in popula-
tion structure might be responsible for one-third of this
increase, the main growth is likely due to the increasing
provision of RRT by governments and health ministries
worldwide. Collectively, these studies suggest that in-
creasing access to dialysis would result in millions more
dialysis patients in South America, Africa, India, China,
and the rest of Asia.
The worldwide nephrology community and health
ministries across the globe must be sober about the sub-
stantial economic challenges involved in closing the RRT
gap. Providing dialysis to all who need it will require
major expenditures in both infrastructure and human
capital. Calculating this cost, especially when it is con-
sidered in terms of cost-effectiveness, is difficult. Recent
small-scale evidence, for example, indicates that provision
of RRT in Japan could be cost-effective [23]. However,
generating cost-effectiveness estimates is a complex
exercise requiring many assumptions that, if incorrect,
can lead to overtly misleading findings and indeed
can be quite controversial [24–26]. Furthermore, cost-
effectiveness findings applicable to one economic sys-
tem are unlikely to apply to another.
A conceptual summary of kidney disease priorities for
higher- and lower-income countries is shown in Table 1.
Priorities in higher-income countries should focus on
improving and refining efforts to detect chronic kidney
disease (CKD) in the hopes of delivering therapies to
slow its progression, thereby preventing advancement to
ESRD. Major efforts should address increasing the num-
ber of living related kidney donors to decrease the preva-
lent dialysis population and, ideally, offer the possibility of
preemptive transplant. Efforts to reduce morbidity and
mortality, especially cardiovascular and infection-related
deaths, should continue apace. Finally, exploration ofTable 1 A conceptual summary of kidney disease priorities for
higher- and lower-income countries
Higher-income countries Lower-income countries
Detect CKD and prevent ESRD Continue to target communicable




Establish physical and human
infrastructure to treat CKD and
perform transplants
Reduced morbidity and
mortality in dialysis patients
Reduce physical, economic, and cultural
barriers to transplant
Seek novel payment models
to reduce costs
Promote PD and home HD and, with
developed countries, seek ways to make
dialysis more affordable and less water
use-intensive
AKI acute kidney injury, CKD chronic kidney disease, ESRD end-stage renal
disease, HD hemodialysis, PD peritoneal dialysismethods to control ever-increasing costs, such as the use
of capitated fees and bundled payment models [27, 28],
must continue. Lower-income countries, in contrast, face
some fundamentally different challenges. They must make
efforts to reduce communicable diseases that can lead to
acute kidney injury (and therefore progressive CKD); at-
tempt to establish the physical health infrastructure,
human professional capital, and cultural acceptance ne-
cessary to perform both deceased donor and living-related
donor kidney transplants; and attempt to develop the abil-
ity to deliver lower-cost and less water-intensive dialytic
therapies such as peritoneal dialysis and home hemo-
dialysis. As the challenges faced by the lower-income
countries are immense, it is likely they will need the assist-
ance of more affluent countries; the developed countries
should take the challenges of lower-income countries ser-
iously and seek technological solutions to make dialysis
more feasible and affordable, especially in rural areas.
Monitoring progress in kidney disease: elements
of an effective framework
Progress in NCDs and in kidney disease is inextricably
linked, albeit in complex ways. The major causes of
CKD and, by extension, ESRD, in developed and in the
increasingly affluent developing countries are, in large
measure, the same causes that contribute to cardiovas-
cular mortality. Hypertension, diabetes, hyperlipidemia,
metabolic syndrome, and inflammation, among other
mechanisms, contribute to both CVD-related death and
to ESRD [29]. Thus, the ESRD population is, in a sense,
“contained” within the CVD sphere. As such, kidney dis-
ease, including ESRD, has now finally become a target
for progress in its own right. In 2011, WHO, via the UN
Political Declaration on NCDs, explicitly recognized the
threat posed by renal disease, stating, in item 19, that “…
renal, oral and eye diseases pose a major health burden
for many countries and that these diseases share common
risk factors and can benefit from common responses to
non-communicable diseases” [30]. In the USA, the
Healthy People 2020 project explicitly lists a series of
chronic kidney disease public health targets [31]. Thus,
kidney disease is now explicitly receiving attention as the
global health challenge that it is.
The question that then arises is how best to guide ef-
forts at improving care. First, certain broad goals should
be established by the worldwide renal health care com-
munity. For countries without universal dialysis access,
expansion of RRT accessibility, especially maintenance
dialysis, should be the first target. This would help re-
duce the immense immediate RRT gap that currently ex-
ists. For countries that have moved beyond this stage,
the goals should include a reduction of ESRD incidence
rates; a reduction in all-cause, cardiovascular, and
infection-related death rates; and a reduction in CVD-
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hospitalizations specifically, and infection-related hospi-
talizations. While improvement in death rates and
hospitalization rates will, paradoxically, appear to in-
crease the societal burden of ESRD by increasing preva-
lent counts, the world should continue to capitalize on
the improvements that have led to the recent lifespan
increases in many developed countries. Concomi-
tantly, efforts to educate the public that this repre-
sents at least partial victory, rather than defeat, are
needed.
Assuming that countries can embark upon these broad
goals, how might progress best be measured? Clearly,
each nation should first be compared with itself, as
WHO does for communicable diseases and NCDs, since
the local social, cultural, and economic milieus vary tre-
mendously by country. Within each country, a useful
and commonly used method of comparing outcomes is
to generate metrics such as standardized morality ratios
(SMRs) and standardized incident ratios, which variously
rely on direct or indirect standardization to adjust for
case-mix differences [32, 33]. Such an approach can be
useful to determine whether and how outcomes vary by
geographic region and whether large variations in care
exist [34]. This approach is widely used in the USA, but
should not be limited to high-income countries, since it
would likely prove useful in middle- or even lower-
income countries where economic development is mark-
edly unequal and the effects of increasing affluence and
access to care are differentially distributed. This is the
case for India and China, where urban and rural health
care environments differ substantially within each coun-
try. Such comparisons would serve to highlight the im-
mense gaps that exist within a country and the need to
address them.
However, additional measures beyond the SMR also
have an important role to play. Overall progress cannot
be measured by SMRs alone, given that they are by na-
ture cross-sectional and, when used to make comparison
rankings, centered at specific values (such as 1.0 or 100)
[35]. SMRs are not particularly informative when care is
likely to be improving across a population as a whole.
An alternative, as used by WHO, is to measure progress
over time within a geographic region, in which each re-
gion serves as its own (temporal) control. The appeal of
this approach is that sites (in this case, countries) that
improve over time, but have not yet reached the level of
higher-performing locales, would not be “penalized” or
disparaged, as can happen when SMRs are the sole
metric used to judge care. A framework whereby each
site acts as its own control would confer several benefits.
First, sites that do not appear to be making sufficient
progress over time would become the appropriate focus
of efforts to improve progress; targeting such sites mightbe a more effective way of improving care for the great-
est number of patients. Second, because simple adjust-
ment for unmodifiable risk factors such as age, sex, race,
and cause of ESRD (as is commonly done when generat-
ing SMRs) provides little insight to guide opportunities
for improvement, the need to investigate other means of
improving care would be highlighted. Third, geographic-
ally related factors that are likely to affect care but are
not explicitly accounted for in SMR adjustment, includ-
ing socioeconomic factors, environmental factors such
as pollution, and local factors such as barriers to care,
idiosyncrasies of care delivery systems, and the local
“cultures” of care held by providers, would be inher-
ently accounted for (since these factors are unlikely
to change rapidly within a geographic unit) by com-
paring geographical units to each other over time.
Collectively, these insights suggest that a combination
of SMRs and time trends may be the most effective
way of monitoring and demonstrating progress over
time.
How might such a system be used in practice? Perhaps
historical trends, over a period of, for example, 5 years
might be used to define reasonable goals for improve-
ment over the ensuing 5-year period. Providers would
then have a “run-in” period of perhaps 1 year in which
to implement quality-improvement efforts designed to
address targeted outcomes. The period used to assess
improvement would then begin, with each area acting as
its own control. Areas that fail to demonstrate progress
over time would then be subject to scrutiny in an
attempt to improve care for the greatest number of
patients.
Conclusions
Many positive developments in overall health outcomes
have occurred over the past decade, but the more afflu-
ent countries have been the disproportionate beneficiar-
ies; as a result, much work needs to be done to decrease
NCD-related deaths in less-affluent countries. Likewise,
more work is required to meet ESRD-related challenges,
which vary by country. In the case of the USA, Canada,
and Western Europe, managing substantial growth in
the prevalent dialysis population is the main difficulty; in
Japan, sustaining the stabilization in the incident counts
and further improving longevity in prevalent patients
should be the main areas of focus; in developing coun-
tries, increasing access to dialysis to reduce the RRT gap
is the greatest challenge. To judge progress on these
fronts, metrics such as the SMR are useful for highlight-
ing geographic and other variations in care where eco-
nomic, geographic, or other disparities exist, while
assessment of trends over time in a given country may
be the best way to determine whether overall efforts to
improve care are effective.
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